Skip to main content

Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis

Calcified Tissue International volume 103, pages 50–54 (2018)Cite this article

Abstract

The aim of the present study was to document the changes in bone mineral density (BMD) 1 year after denosumab loss-of-effect following long-term treatment with subcutaneous denosumab 60 mg Q6M during 7 or 10 years and in the absence of any treatment with a bone active substance. All postmenopausal women with osteoporosis who participated to the randomized placebo-controlled FREEDOM core trial and its open-label extension at the University Hospital of Bern, Switzerland, and who accepted to undergo off-treatment follow-up during 1 year after discontinuation, were included (N = 12). After 10 years of denosumab, mean lumbar spine (LS) BMD had increased by 21.2% vs. baseline. One year after discontinuation LS BMD had decreased by − 9.1% vs. Year 10, resulting in a net gain of 10.2% vs. baseline. At total hip (TH) and femoral neck (FN), BMD had increased by 8.3 and 8.1% in Year 10 vs. baseline, respectively. 1 Year after discontinuation, BMD had decreased by − 12.7 and − 11.0% vs. Year 10, respectively, corresponding to net BMD losses of − 5.5 and − 3.8% vs. baseline, respectively. Similar albeit less pronounced changes were observed in those treated with denosumab during 7 years. Stopping denosumab after long-term exposure resulted in BMD losses of large order of magnitude at all measured sites, suggesting that treatment duration may predict the rate and amount of bone lost.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222–229

    Article  PubMed  CAS  Google Scholar 

  2. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972–980

    Article  PubMed  CAS  Google Scholar 

  3. Brown JP, Roux C, Torring O, Ho PR, Beck Jensen JE, Gilchrist N, Recknor C, Austin M, Wang A, Grauer A, Wagman RB (2013) Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res 28:746–752

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Anastasilakis AD, Makras P (2016) Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int 27:1929–1930

    Article  PubMed  CAS  Google Scholar 

  5. Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O (2016) Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 27:1923–1925

    Article  PubMed  CAS  Google Scholar 

  6. Popp AW, Zysset PK, Lippuner K (2016) Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int 27:1917–1921

    Article  PubMed  CAS  Google Scholar 

  7. Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, Roux C, Torring O, Valter I, Wang AT, Brown JP (2017) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. https://doi.org/10.1002/jbmr.3337

    Article  PubMed  Google Scholar 

  8. Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26:530–537

    Article  PubMed  CAS  Google Scholar 

  9. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, Trial F (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New Engl J Med 361:756–765

    Article  PubMed  CAS  Google Scholar 

  10. Bolognese MA, Teglbjaerg CS, Zanchetta JR, Lippuner K, McClung MR, Brandi ML, Hoiseth A, Lakatos P, Moffett AH, Lorenc RS, Wang A, Libanati C (2013) Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. J Clin Densitom 16:147–153

    Article  PubMed  Google Scholar 

  11. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Man Z, Mellstrom D, Radominski SC, Reginster JY, Resch H, Roman Ivorra JA, Roux C, Vittinghoff E, Austin M, Daizadeh N, Bradley MN, Grauer A, Cummings SR, Bone HG (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694–701

    Article  PubMed  CAS  Google Scholar 

  12. Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, Brandi ML, Czerwinski E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int 26:2773–2783

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwinski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 Years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diab Endocrinol 5:513–523

    Article  CAS  Google Scholar 

  14. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New Engl J Med 361:756–765

    Article  PubMed  CAS  Google Scholar 

  15. Lippuner K, Johansson H, Kanis JA, Rizzoli R (2010) FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21:381–389

    Article  PubMed  CAS  Google Scholar 

  16. Uebelhart B, Rizzoli R, Ferrari SL (2017) Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. Osteoporos Int 28:2701–2705

    Article  PubMed  CAS  Google Scholar 

  17. McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28:1723–1732

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Leder BZ, Tsai JN, Jiang LA, Lee H (2017) Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the denosumab and teriparatide follow-up study (DATA-follow-up). Bone 98:54–58

    Article  PubMed  CAS  Google Scholar 

  19. Reid IR, Horne AM, Mihov B, Gamble GD (2017) Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int 101:371–374

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We are grateful to Philippe Kress, M.D., Glattbrugg, Switzerland, for his critical comments and review of the manuscript. Full access to source data was granted by Amgen Inc, Thousand Oaks, CA 91320, USA who did not sponsor the analysis and publication and had no influence on the results and contents of the manuscript. The authors have full control of all primary data and agree to allow the journal to review these data upon request.

Author information

Affiliations

  1. Department of Osteoporosis, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Switzerland

    Albrecht Werner Popp, Nadshathra Varathan, Helene Buffat, Christoph Senn, Romain Perrelet & Kurt Lippuner

Authors
  1. Albrecht Werner Popp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nadshathra Varathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Helene Buffat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christoph Senn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Romain Perrelet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kurt Lippuner
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study design: AP and KL. Study conduct: AP and CS. Data collection: NV, RP, AP. Data analysis: AP and RP. Data interpretation: AP and KL. Drafting manuscript: AP. Revising manuscript content: AP, NV, HB, CS, RP, KL. Approving final version of manuscript: AP, NV, HB, CS, RP, KL. KL takes responsibility for the integrity of the data analysis.

Corresponding author

Correspondence to Kurt Lippuner.

Ethics declarations

Conflict of interest

Kurt Lippuner is a primary investigator in clinical development programs in the field of osteoporosis from Amgen. Albrecht Popp and Christoph Senn are Sub-Investigators in clinical development programs in the field of osteoporosis from Amgen, Albrecht Popp has received personal fees for participation in advisory board meetings from Amgen Switzerland and Labatech Pharma. Nadshathra Varathan and Romain Perrelet declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This study was approved by the cantonal ethical review committee of Bern, Switzerland. All participants have provided their written informed consent. The study was carried out in accordance with the principles enunciated in the current version of the Declaration of Helsinki (DoH), the Essentials of Good Epidemiological Practice issued by Public Health Schweiz (EGEP), the Swiss Law and Swiss regulatory authority’s requirements as applicable.

Electronic Supplementary material

Below is the link to the electronic supplementary material.

Patient disposition (TIFF 1521 KB)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Popp, A.W., Varathan, N., Buffat, H. et al. Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis. Calcif Tissue Int 103, 50–54 (2018). https://doi.org/10.1007/s00223-018-0394-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-018-0394-4

Keywords

  • Osteoporosis
  • Denosumab
  • Bone mineral density
  • Long-term therapy
  • Rebound-associated bone loss